KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) EBT (2018 - 2025)

Castle Biosciences' EBT history spans 7 years, with the latest figure at -$2.7 million for Q4 2025.

  • For Q4 2025, EBT fell 134.42% year-over-year to -$2.7 million; the TTM value through Dec 2025 reached -$29.5 million, down 236.87%, while the annual FY2025 figure was -$29.5 million, 236.87% down from the prior year.
  • EBT for Q4 2025 was -$2.7 million at Castle Biosciences, down from -$386000.0 in the prior quarter.
  • Across five years, EBT topped out at $8.3 million in Q3 2024 and bottomed at -$29.2 million in Q1 2023.
  • The 5-year median for EBT is -$5.6 million (2021), against an average of -$8.7 million.
  • The largest annual shift saw EBT skyrocketed 410.31% in 2024 before it crashed 955.48% in 2025.
  • A 5-year view of EBT shows it stood at -$15.2 million in 2021, then plummeted by 35.67% to -$20.6 million in 2022, then soared by 87.64% to -$2.5 million in 2023, then surged by 410.31% to $7.9 million in 2024, then plummeted by 134.42% to -$2.7 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's EBT are -$2.7 million (Q4 2025), -$386000.0 (Q3 2025), and -$143000.0 (Q2 2025).